3 August 2022 - The high costs of cancer drugs impact patients negatively. In fact, the out of pocket cost burden can be “financially toxic” to patients, causing personal bankruptcy or simply take a substantial bite out of people’s discretionary income.

Should the Inflation Reduction Act pass later this month, the imposition of a $2,000 cap on Medicare beneficiary out-of-pocket spending on outpatient drugs would address the issue of financial toxicity to some degree, at least for one segment (Medicare) of the market.

Read Forbes article